A Phase 1 interventional study of Carfilzomib and Dexamethasone in Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma and Hodgkin's Disease, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-02.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 419 studies in Waldenstrom Macroglobulinemia with a site in United States — 34 open to participants now, 57 under way, 1 of them phase 3. Waldenstrom Macroglobulinemia · United States.
Among the 419 studies in Waldenstrom Macroglobulinemia with a site in United States, this one is the 132nd largest by enrollment of the 365 interventional ones that give a count, is one of 23 that started in 2005, is one of 140 in phase 1, and was the 136th registered.
524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.
Browse Waldenstrom Macroglobulinemia studies →34 of the 419 studies in Waldenstrom Macroglobulinemia with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Australia, France and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Canada and 9 more countries
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Ascentage Pharma Group Inc. · Sites in United States, China
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
419 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 188 · Phase 2 210 · Phase 3 20 · Phase 4 2
First in 1988; this study’s year is marked. 23 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 39 across 429 interventional studies indexed under Waldenstrom Macroglobulinemia.
Median enrollment 37 across the 365 interventional studies, 106 across the 24 observational. Of the 339 that completed or were terminated, 144 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 419 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 2 studies filed under Waldenstrom Macroglobulinemia — fewer than ten, so there is no comparison to draw.
17 of the studies in Waldenstrom Macroglobulinemia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT05640102BeiGeneObservational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia | 2026-12 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT05065554Shayna Sarosiek, MDACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | 2026-12-01 |
| NCT06561347Massachusetts General HospitalZanubrutinib, Bendamustine, Rituximab Prev. Untreated WM | 2026-12-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 419 studies in Waldenstrom Macroglobulinemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's macroglobulinemia. Carfilzomib is a proteasome inhibitor, an enzyme responsible for degrading a wide variety of cellular proteins.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed diagnosis of one of the hematologic below:
Total white blood cell (WBC) count ≥ 2,000/mm³, (ANC) ≥ 1000/mm³, ≥ 8.0 g/dL, and count ≥ 50,000/mm³
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
Drug: Carfilzomib
Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
Drug: Carfilzomib
Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
Drug: Carfilzomib
Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
Drug: Carfilzomib
Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
Drug: Carfilzomib
Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
Drug: Carfilzomib
Participants received carfilzomib 115.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
Drug: Carfilzomib
Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
Drug: Carfilzomib
Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles. Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e. 40 mg weekly).
Drug: Carfilzomib · Drug: Dexamethasone
Administered as an IV bolus dose
Also known as: PR-171, Kyprolis
Administered orally prior to carfilzomib
Number of Participants With Dose-limiting Toxicities (DLTs)
A DLT was defined as any of the following occurring in the first 28 days of study participation: Nonhematologic: * \> Grade 2 neuropathy with pain * ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, or diarrhea) * ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic/antidiarrheal therapy Hematologic: * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 0.5 × 10ˆ9/L) lasting ≥ 14 days without hematopoietic growth factor support * Febrile neutropenia (ANC \< 1.0 × 10ˆ9/L with a fever ≥ 38.3°C) * Grade 4 thrombocytopenia (platelets \< 25.0 × 10ˆ9/L) or thrombocytopenia associated with bleeding. Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 3.0.
Time frame: 28 days
Maximum Observed Plasma Concentration of Carfilzomib (Cmax)
Time frame: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Time to Maximum Observed Plasma Concentration of Carfilzomib (Tmax)
Time frame: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Area Under the Concentration-time Curve to Last Measureable Timepoint (AUClast) for Carfilzomib
Time frame: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) for Carfilzomib
Time frame: Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Best Clinical Response to Treatment
Disease response criteria for NHL were according to the International Working Group Criteria for Non-Hodgkin's Lymphoma. Disease response criteria for Multiple Myeloma were according to the European Group for Blood and Marrow Transplantation (EBMT). Disease response criteria for WM were according to the consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. The disease response criteria for Hodgkin's Lymphoma are defined as follows: * Complete response: total resolution of measurable disease parameters. * Partial response: a ≥ 50% resolution without the appearance of new disease. * Stable disease: between \< 50% resolution and ≤ 25% increases in measurable disease parameters without appearance of new disease. * Progressive disease: an increase of \> 25% in measurable disease parameters. Best clinical response is the best response observed from the start of study treatment until disease progression or death.
Time frame: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
Duration of Response
Duration of objective response is defined as the time from the date of first documented assessment of clinical response (confirmed or unconfirmed complete response, partial response, or minimal response) to the date of documented assessment of progressive disease or death, whichever comes first, plus one day. Participants without tumor progression or death were censored at the date of their last valid clinical response assessment. Median duration of response was calculated using the Kaplan-Meier method.
Time frame: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
Time to Progression
Time to progressive disease is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease, plus one day. Participants without tumor progression were censored at the date of their last clinical response assessment. Median time to progression was calculated using the Kaplan-Meier method.
Time frame: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
Progression-free Survival
Progression-free survival is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease or death, whichever comes first, plus one day. Participants without tumor progression or death were censored at the date of their last valid clinical response assessment. Median progression-free survival was calculated using the Kaplan-Meier method.
Time frame: From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
Adults with with multiple myeloma (MM)-both secretory and nonsecretory, non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), or Waldenström's macroglobulinemia (WM) were eligible for enrollment in this study.
| Milestone | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 8 | 6 | 7 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Not completed | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 8 | 6 | 6 | 3 |
| Withdrew: Disease progression or relapse | 3 | 1 | 2 | 1 | 2 | 2 | 3 | 5 | 5 | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
A DLT was defined as any of the following occurring in the first 28 days of study participation: Nonhematologic: * \> Grade 2 neuropathy with pain * ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, or diarrhea) * ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic/antidiarrheal therapy Hematologic: * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 0.5 × 10ˆ9/L) lasting ≥ 14 days without hematopoietic growth factor support * Febrile neutropenia (ANC \< 1.0 × 10ˆ9/L with a fever ≥ 38.3°C) * Grade 4 thrombocytopenia (platelets \< 25.0 × 10ˆ9/L) or thrombocytopenia associated with bleeding. Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 3.0.
| participants | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| ng/mL | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² (±DEX) |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration of Carfilzomib (Cmax) | — | — | — | — | — | 505.17 ± 485.12 | 142.67 ± 97.22 | 527.50 ± 405.59 | 406.08 ± 517.29 | 390.66 ± 492.92 |
Disease response criteria for NHL were according to the International Working Group Criteria for Non-Hodgkin's Lymphoma. Disease response criteria for Multiple Myeloma were according to the European Group for Blood and Marrow Transplantation (EBMT). Disease response criteria for WM were according to the consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. The disease response criteria for Hodgkin's Lymphoma are defined as follows: * Complete response: total resolution of measurable disease parameters. * Partial response: a ≥ 50% resolution without the appearance of new disease. * Stable disease: between \< 50% resolution and ≤ 25% increases in measurable disease parameters without appearance of new disease. * Progressive disease: an increase of \> 25% in measurable disease parameters. Best clinical response is the best response observed from the start of study treatment until disease progression or death.
| participants | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial Response | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 0 |
| Minimal Response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Stable Disease/No Change | 0 | 1 | 1 | 2 | 1 | 1 | 0 | 2 | 1 | 2 | 0 |
| Progressive Disease | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 3 | 1 | 2 | 2 |
| Unknown | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Duration of objective response is defined as the time from the date of first documented assessment of clinical response (confirmed or unconfirmed complete response, partial response, or minimal response) to the date of documented assessment of progressive disease or death, whichever comes first, plus one day. Participants without tumor progression or death were censored at the date of their last valid clinical response assessment. Median duration of response was calculated using the Kaplan-Meier method.
| days | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response | — | — | — | — | — | — | 308.0 (308.0 to 308.0) | 176.0 (176.0 to 176.0) | 225.0 (94.0 to 316.0) | NA (NA to NA) | NA (NA to NA) |
Time to progressive disease is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease, plus one day. Participants without tumor progression were censored at the date of their last clinical response assessment. Median time to progression was calculated using the Kaplan-Meier method.
| days | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Progression | 114.0 (114.0 to 114.0) | 232.0 (57.0 to 407.0) | NA (54.0 to 54.0) | NA (NA to NA) | 55.0 (47.0 to 55.0) | 48.0 (15.0 to 176.0) | 186.0 (50.0 to 322.0) | 110.5 (15.0 to 190.0) | 225.0 (36.0 to 330.0) | NA (15.0 to 99.0) | 49.0 (23.0 to 49.0) |
Progression-free survival is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease or death, whichever comes first, plus one day. Participants without tumor progression or death were censored at the date of their last valid clinical response assessment. Median progression-free survival was calculated using the Kaplan-Meier method.
| days | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression-free Survival | 114.0 (114.0 to 114.0) | 232.0 (57.0 to 407.0) | NA (54.0 to 54.0) | NA (NA to NA) | 55.0 (47.0 to 55.0) | 48.0 (15.0 to 176.0) | 186.0 (50.0 to 322.0) | 110.5 (15.0 to 190.0) | 225.0 (36.0 to 330.0) | NA (15.0 to 99.0) | 49.0 (23.0 to 49.0) |
| minutes | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² (±DEX) |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Maximum Observed Plasma Concentration of Carfilzomib (Tmax) | — | — | — | — | — | 5 ± 0 | 6 ± 1 | 7 ± 2 | 6 ± 2 | 16 ± 11 |
| ng*minute/mL | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² (±DEX) |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve to Last Measureable Timepoint (AUClast) for Carfilzomib | — | — | — | — | — | 4049 ± 3695 | 1414 ± 919 | 4911 ± 3495 | 3409 ± 3964 | 4970 ± 5817 |
| ng*minute/mL | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² (±DEX) |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) for Carfilzomib | — | — | — | — | — | 4056 ± 3698 | 1420 ± 922 | 4942 ± 3497 | 3417 ± 3962 | 4997 ± 5812 |
Collected over From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CFZ 1.2 mg/m² | — | 2/3 (66.7%) | 3/3 (100%) |
| CFZ 2.4 mg/m² | — | 1/3 (33.3%) | 3/3 (100%) |
| CFZ 4.0 mg/m² | — | 3/4 (75%) | 4/4 (100%) |
| CFZ 6.0 mg/m² | — | 2/3 (66.7%) | 3/3 (100%) |
| CFZ 8.4 mg/m² | — | 2/3 (66.7%) | 3/3 (100%) |
| CFZ 11.0 mg/m² | — | 2/4 (50%) | 4/4 (100%) |
| CFZ 15.0 mg/m² | — | 1/3 (33.3%) | 3/3 (100%) |
| CFZ 20.0 mg/m² | — | 3/8 (37.5%) | 8/8 (100%) |
| CFZ 27.0 mg/m² | — | 4/6 (66.7%) | 6/6 (100%) |
| CFZ 20/27 mg/m² | — | 3/7 (42.9%) | 7/7 (100%) |
| CFZ 20/27 mg/m² + DEX | — | 2/4 (50%) | 4/4 (100%) |
| Event | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 1/4 | 0/3 | 1/3 | 0/4 | 0/3 | 0/8 | 0/6 | 0/7 | 0/4 |
| Hyperviscosity syndromeBlood and lymphatic system disorders | 0/3 | 0/3 | 0/4 | 0/3 | 0/3 | 0/4 | 1/3 | 0/8 | 0/6 | 0/7 | 0/4 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 0/4 | 1/3 | 0/3 | 0/4 | 0/3 | 0/8 | 0/6 | 0/7 | 0/4 |
| BronchitisInfections and infestations | 0/3 | 0/3 | 0/4 | 0/3 | 1/3 | 0/4 | 0/3 | 0/8 | 0/6 | 0/7 | 0/4 |
| PneumoniaInfections and infestations | 1/3 | 1/3 | 1/4 | 0/3 | 1/3 | 0/4 | 0/3 | 0/8 | 0/6 | 0/7 | 0/4 |
| SepsisInfections and infestations | 0/3 | 1/3 | 0/4 | 0/3 | 0/3 | 0/4 | 0/3 | 0/8 | 0/6 | 0/7 | 0/4 |
| Septic shockInfections and infestations | 0/3 | 0/3 | 0/4 | 0/3 | 1/3 | 0/4 | 0/3 | 0/8 | 0/6 | 0/7 | 0/4 |
| SinusitisInfections and infestations | 1/3 | 0/3 | 0/4 | 1/3 | 0/3 | 0/4 | 0/3 | 0/8 | 0/6 | 0/7 | 0/4 |
| Aspartate aminotransferase increasedInvestigations | 1/3 | 0/3 | 0/4 | 0/3 | 0/3 | 0/4 | 0/3 | 0/8 | 0/6 | 0/7 | 0/4 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 0/3 | 0/4 | 1/3 | 0/3 | 0/4 | 0/3 | 0/8 | 0/6 | 0/7 | 0/4 |
| Event | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/3 | 3/3 | 0/4 | 2/3 | 0/3 | 1/4 | 2/3 | 4/8 | 4/6 | 4/7 | 4/4 |
| NauseaGastrointestinal disorders | 2/3 | 0/3 | 3/4 | 1/3 | 2/3 | 2/4 | 3/3 | 5/8 | 4/6 | 3/7 | 0/4 |
| FatigueGeneral disorders | 2/3 | 0/3 | 3/4 | 1/3 | 1/3 | 3/4 | 3/3 | 3/8 | 3/6 | 4/7 | 1/4 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/3 | 1/3 | 2/4 | 1/3 | 3/3 | 2/4 | 1/3 | 0/8 | 4/6 | 3/7 | 1/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/4 | 1/3 | 0/3 | 0/4 | 1/3 | 0/8 | 5/6 | 0/7 | 1/4 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 1/3 | 3/4 | 1/3 | 0/3 | 1/4 | 0/3 | 3/8 | 3/6 | 4/7 | 3/4 |
| VomitingGastrointestinal disorders | 0/3 | 0/3 | 3/4 | 2/3 | 1/3 | 3/4 | 1/3 | 2/8 | 1/6 | 1/7 | 0/4 |
| PyrexiaGeneral disorders | 1/3 | 1/3 | 3/4 | 0/3 | 1/3 | 1/4 | 2/3 | 2/8 | 3/6 | 3/7 | 0/4 |
| Vision blurredEye disorders | 2/3 | 0/3 | 0/4 | 0/3 | 0/3 | 0/4 | 1/3 | 1/8 | 0/6 | 0/7 | 0/4 |
| ConstipationGastrointestinal disorders | 2/3 | 0/3 | 2/4 | 1/3 | 2/3 | 2/4 | 0/3 | 4/8 | 3/6 | 2/7 | 0/4 |
| Age, Continuous(years) | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation (Part 1) | 62.5 ± 17.47 | 69.6 ± 4.80 | 55.3 ± 21.71 | 51.7 ± 6.20 | 61.6 ± 9.15 | 61.3 ± 3.76 | 50.3 ± 12.99 | 60.6 ± 11.99 | 67.6 ± 9.82 | NA ± NA | NA ± NA | 60.6 ± 12.25 |
| Dose Expansion (Part 2) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 66.3 ± 9.21 | 54.3 ± 13.57 | 61.9 ± 11.96 |
| Sex: Female, Male(Participants) | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 2 | 3 | 2 | 1 | 4 | 1 | 2 | 2 | 2 | 3 | 22 |
| Male | 3 | 1 | 1 | 1 | 2 | 0 | 2 | 6 | 4 | 5 | 1 | 26 |
| Race/Ethnicity, Customized(participants) | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| African American | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| Caucasian | 3 | 2 | 3 | 3 | 2 | 4 | 3 | 7 | 6 | 6 | 3 | 42 |
| Hispanic | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native American | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Disease Diagnosis(participants) | CFZ 1.2 mg/m² | CFZ 2.4 mg/m² | CFZ 4.0 mg/m² | CFZ 6.0 mg/m² | CFZ 8.4 mg/m² | CFZ 11.0 mg/m² | CFZ 15.0 mg/m² | CFZ 20.0 mg/m² | CFZ 27.0 mg/m² | CFZ 20/27 mg/m² | CFZ 20/27 mg/m² + DEX | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Multiple Myeloma | 0 | 3 | 0 | 2 | 1 | 2 | 2 | 6 | 5 | 3 | 4 | 28 |
| Non-Hodgkin's Lymphoma | 3 | 0 | 3 | 1 | 2 | 2 | 1 | 2 | 1 | 2 | 0 | 17 |
| Waldenstrom's Macroglobulinemia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| Hodgkin's Disease | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
The record gives a start of Sep 2005, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 6 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carfilzomib
Waldenstrom Macroglobulinemia →